Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-coding transcript regulating alternative splicing (NTRAS), also called LINC01693 or RP11-354K1.1, is a long non-coding RNA (lncRNA) that does not encode a protein but plays a functional role in RNA regulation within the cell. NTRAS is known to regulate alternative splicing by interacting with splicing and transcription factors, and can alternatively affect gene expression, either via enhancer or promoter regions. It has documented roles in maintaining vascular integrity and is upregulated in certain cancer types, suggesting relevance in oncology and cardiovascular biology. It is not currently considered a therapeutic target such as a receptor, enzyme, or transporter, and there are no known drugs that directly interact with it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-coding transcript regulating alternative splicing (NTRAS).